Skip to main content
Erschienen in: Annals of Surgical Oncology 4/2017

15.11.2016 | Breast Oncology

Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? Five-Year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial: Assessment and Incidence of True Lymphedema

verfasst von: Neil Wetzig, MB BS, FRCS, FRACS, Peter Grantley Gill, MB BS, MD, FRACS, David Espinoza, BArch, BSc, Rebecca Mister, Bsc, MSc, Martin R. Stockler, MB BS, MSc, FRACP, Val J. Gebski, BA, MStat, Owen A. Ung, MB BS, FRACP, Ian Campbell, MB ChB, FRACS, John Simes, MD, BSc(Med), SM, FRACP

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine whether the benefits of sentinel-node-based management (SNBM) over routine axillary clearance (RAC) persisted to 5 years.

Methods

A total of 1088 women with breast cancer less than 3 cm in diameter and clinically negative axillary nodes were randomized to SNBM with axillary clearance if the sentinel node was positive or RAC preceded by sentinel-node biopsy. The outcomes were: (1) objectively measured change in the volume of the operated and contralateral nonoperated arms; (2) the proportion with an increase in arm volume <15%; and (3) subjectively assessed arm morbidity for the domains swelling, symptoms, dysfunction, and disability. Assessments were performed at 1 and 6 months after surgery and then annually.

Results

Limb volume increased progressively in the operated and nonoperated arms for 2 years and persisted unchanged to year 5, accompanied by weight gain. Correction by change in the nonoperated arm showed a mean volume increase of 70 mL in the RAC group and 26 mL in the SNBM group (P < 0.001) at 5 years. Only 28 patients (3.3%) had a corrected increase >15% from baseline (RAC 5.0% vs. SNBM 1.7%). Significant predictors were surgery type (RAC vs. SNBM), obesity, diabetes, palpable tumor, and weight gain exceeding 10% of baseline value.

Conclusions

Subjective assessments revealed persisting patient concerns about swelling and symptoms but not overall disability at 5 years. Subjective scores were only moderately correlated with volume increase. SNAC1 has demonstrated that objective morbidity and subjective morbidity persist for 5 years after surgery and that SNBM significantly lowers the risk of both.
Literatur
1.
Zurück zum Zitat Gill PG, Wetzig N, Gebski V, et al, and the SNAC Trial Group. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol. 2009;16:266–75. Gill PG, Wetzig N, Gebski V, et al, and the SNAC Trial Group. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol. 2009;16:266–75.
2.
Zurück zum Zitat Elmadahm AA, Gill PG, Bochner M, Gebski V, Zannino D, Wetzig N, Campbell I, Stockler M, Ung O, Simes J, Uren R.. Identification of the Sentinel Lymph Node in the SNAC-1 Trial. ANZ J Surg. 2015;85(1–2):58–63.CrossRefPubMed Elmadahm AA, Gill PG, Bochner M, Gebski V, Zannino D, Wetzig N, Campbell I, Stockler M, Ung O, Simes J, Uren R.. Identification of the Sentinel Lymph Node in the SNAC-1 Trial. ANZ J Surg. 2015;85(1–2):58–63.CrossRefPubMed
3.
Zurück zum Zitat Tewari N, Gill P G, Bochner M, Kollias J. Comparison of volume displacement versus circumferential upper limb measurements for lymphoedema: implications for the SNAC trial. ANZ J Surg. 2008;78:889–93.CrossRefPubMed Tewari N, Gill P G, Bochner M, Kollias J. Comparison of volume displacement versus circumferential upper limb measurements for lymphoedema: implications for the SNAC trial. ANZ J Surg. 2008;78:889–93.CrossRefPubMed
4.
Zurück zum Zitat Smith MJ, Gill PG, Wetzig N, et al. Comparing patients’ and clinicians’ assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Res Treat. 2008;117:99–109.CrossRefPubMed Smith MJ, Gill PG, Wetzig N, et al. Comparing patients’ and clinicians’ assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Res Treat. 2008;117:99–109.CrossRefPubMed
5.
Zurück zum Zitat Wetzig N, Gill PG, Zanno D, Stockler MR, Gebski V, Ung O, Campbell I, Simes J. Sentinel-lymph-node-based management or routine axillary clearance? Three-year outcomes of the RACS sentinel node biopsy versus axillary clearance (SNAC) 1 trial. Ann Surg Oncol. 2014;16:266–75. Wetzig N, Gill PG, Zanno D, Stockler MR, Gebski V, Ung O, Campbell I, Simes J. Sentinel-lymph-node-based management or routine axillary clearance? Three-year outcomes of the RACS sentinel node biopsy versus axillary clearance (SNAC) 1 trial. Ann Surg Oncol. 2014;16:266–75.
6.
Zurück zum Zitat Mansel RE, Fallowfield LJ, Kissin M. Randomised multicentre trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98(9):599–609.CrossRefPubMed Mansel RE, Fallowfield LJ, Kissin M. Randomised multicentre trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98(9):599–609.CrossRefPubMed
7.
Zurück zum Zitat Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13(4):491–500.CrossRefPubMed Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13(4):491–500.CrossRefPubMed
8.
Zurück zum Zitat Hack TF, Kwan WB, Thomas-MacLean JL, Towers A, Miedema B, Tilley A, et al. Predictors of arm morbidity following breast cancer surgery. Psycho-Oncology. 2010;19(11):1205–12.CrossRefPubMed Hack TF, Kwan WB, Thomas-MacLean JL, Towers A, Miedema B, Tilley A, et al. Predictors of arm morbidity following breast cancer surgery. Psycho-Oncology. 2010;19(11):1205–12.CrossRefPubMed
9.
Zurück zum Zitat Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. J Natl Cancer Inst. 2001;93(2):96–111.CrossRefPubMed Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. J Natl Cancer Inst. 2001;93(2):96–111.CrossRefPubMed
10.
Zurück zum Zitat Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111–8.CrossRefPubMedPubMedCentral Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111–8.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Coen JJ, Taghian AG, Kachnic LA, Coen JJ, Assaad SI. Risk of lymphoedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2003;55(5):1209–15.CrossRefPubMed Coen JJ, Taghian AG, Kachnic LA, Coen JJ, Assaad SI. Risk of lymphoedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2003;55(5):1209–15.CrossRefPubMed
12.
Zurück zum Zitat Dayes IS, Levine MN, Julian JA, Pritchard KI, D’Souza DP, Kligman L, et al. Lymphoedema in women with breast cancer: characteristics of patients screened for a randomized trial. Breast Cancer Res Treat. 2008;110(2):337–42.CrossRefPubMed Dayes IS, Levine MN, Julian JA, Pritchard KI, D’Souza DP, Kligman L, et al. Lymphoedema in women with breast cancer: characteristics of patients screened for a randomized trial. Breast Cancer Res Treat. 2008;110(2):337–42.CrossRefPubMed
13.
Zurück zum Zitat McLaughlin SA, Wright MJ, Morris KT. Prevalence of lymphoedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviours. J Clin Oncol. 2008;26(32):5220–6.CrossRefPubMedPubMedCentral McLaughlin SA, Wright MJ, Morris KT. Prevalence of lymphoedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviours. J Clin Oncol. 2008;26(32):5220–6.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Kissin M, Querci-Della-Rovere G, Easton D, Westbury G. Risk of lymphoedema following the treatment for breast cancer. BJS. 1986;73:580–4.CrossRef Kissin M, Querci-Della-Rovere G, Easton D, Westbury G. Risk of lymphoedema following the treatment for breast cancer. BJS. 1986;73:580–4.CrossRef
15.
Zurück zum Zitat Larson D, Weinstein M, Goldburg L, Silver B, Recht A, Cady Y. Oedema of the arm as a function of the extent of axillary surgery in patients with stage 1-2 carcinoma of the breast treated primary radiotherapy. Int J Radiat Oncol Biol Phys. 1986:12;1575–82.CrossRefPubMed Larson D, Weinstein M, Goldburg L, Silver B, Recht A, Cady Y. Oedema of the arm as a function of the extent of axillary surgery in patients with stage 1-2 carcinoma of the breast treated primary radiotherapy. Int J Radiat Oncol Biol Phys. 1986:12;1575–82.CrossRefPubMed
16.
Zurück zum Zitat Liljegren G, Holmburg L. Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage 1: results from a randomised trial. Eur J Cancer. 1997;33;193–9.CrossRefPubMed Liljegren G, Holmburg L. Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage 1: results from a randomised trial. Eur J Cancer. 1997;33;193–9.CrossRefPubMed
17.
Zurück zum Zitat Helyer LK, Varnic M, Le LW, Leong W, McCready D. Obesity is a risk factor for developing postoperative lymphoedema in breast cancer patients. Breast J. 2010;16(1):48–54.CrossRefPubMed Helyer LK, Varnic M, Le LW, Leong W, McCready D. Obesity is a risk factor for developing postoperative lymphoedema in breast cancer patients. Breast J. 2010;16(1):48–54.CrossRefPubMed
18.
Zurück zum Zitat Herd-Smith A, Russo A, Muraca MG, Del Turco MR, Cardona G. Prognostic factors for lymphoedema after primary treatment of breast carcinoma. Cancer. 2001;92(7):1783–7.CrossRefPubMed Herd-Smith A, Russo A, Muraca MG, Del Turco MR, Cardona G. Prognostic factors for lymphoedema after primary treatment of breast carcinoma. Cancer. 2001;92(7):1783–7.CrossRefPubMed
19.
Zurück zum Zitat Soran A, D’Angelo G, Begovic M, Ardic F, Harlak A, Samuel Wieand H, et al. Breast cancer-related lymphoedema—what are the significant predictors and how they affect the severity of lymphoedema? Breast J. 2006;12(6):536–43.CrossRefPubMed Soran A, D’Angelo G, Begovic M, Ardic F, Harlak A, Samuel Wieand H, et al. Breast cancer-related lymphoedema—what are the significant predictors and how they affect the severity of lymphoedema? Breast J. 2006;12(6):536–43.CrossRefPubMed
20.
Zurück zum Zitat Aitken R, Gayes M, Rodger A, Chattey U, Forrest A. Arm morbidity within a trial of mastectomy and either node sample with selective radiotherapy or axillary clearance. BJS. 1989;76:568–71.CrossRef Aitken R, Gayes M, Rodger A, Chattey U, Forrest A. Arm morbidity within a trial of mastectomy and either node sample with selective radiotherapy or axillary clearance. BJS. 1989;76:568–71.CrossRef
21.
Zurück zum Zitat Tsai RJ, Dennis LK, Lynch CF, Snetselaar LG, Zamba GK, Scott-Conner C. The risk of developing arm lymphoedema among breast cancer survivors: a meta-analysis of treatment factors. Ann Surg Oncol. 2009;16(7):1959–72.CrossRefPubMed Tsai RJ, Dennis LK, Lynch CF, Snetselaar LG, Zamba GK, Scott-Conner C. The risk of developing arm lymphoedema among breast cancer survivors: a meta-analysis of treatment factors. Ann Surg Oncol. 2009;16(7):1959–72.CrossRefPubMed
22.
Zurück zum Zitat Villarini A, Pasanisi P, Raimondi M, Gargano G, Bruno E, Morelli D, et al. Preventing weight gain during adjuvant chemotherapy for breast cancer: a dietary intervention study. Breast Cancer Res Treat. 2012;135:581–9.CrossRefPubMed Villarini A, Pasanisi P, Raimondi M, Gargano G, Bruno E, Morelli D, et al. Preventing weight gain during adjuvant chemotherapy for breast cancer: a dietary intervention study. Breast Cancer Res Treat. 2012;135:581–9.CrossRefPubMed
23.
Zurück zum Zitat Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J. Weight change associated with Anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Res Treat. 2012;134:727–37.CrossRefPubMed Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J. Weight change associated with Anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Res Treat. 2012;134:727–37.CrossRefPubMed
24.
Zurück zum Zitat Kopec JA, Colangelo LH, Land SR, Julian TB, Brown AM, Anderson SJ, et al. Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32. J Support Oncol. 2013;11(1):22–30.PubMedPubMedCentral Kopec JA, Colangelo LH, Land SR, Julian TB, Brown AM, Anderson SJ, et al. Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32. J Support Oncol. 2013;11(1):22–30.PubMedPubMedCentral
Metadaten
Titel
Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? Five-Year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial: Assessment and Incidence of True Lymphedema
verfasst von
Neil Wetzig, MB BS, FRCS, FRACS
Peter Grantley Gill, MB BS, MD, FRACS
David Espinoza, BArch, BSc
Rebecca Mister, Bsc, MSc
Martin R. Stockler, MB BS, MSc, FRACP
Val J. Gebski, BA, MStat
Owen A. Ung, MB BS, FRACP
Ian Campbell, MB ChB, FRACS
John Simes, MD, BSc(Med), SM, FRACP
Publikationsdatum
15.11.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2017
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5669-2

Weitere Artikel der Ausgabe 4/2017

Annals of Surgical Oncology 4/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.